DUBLIN, July 21, 2021--(BUSINESS WIRE)--The "Global Urticaria Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
Urticaria Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Urticaria market.
It covers emerging therapies for Urticaria in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Urticaria pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Urticaria pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Urticaria pipeline products by the company.
Short-term Launch Highlights:
Find out which Urticaria pipeline products will be launched in the US and Ex-US till 2025.
Urticaria phase 3 clinical trial pipeline products
Urticaria phase 2 clinical trial pipeline products
Urticaria phase 1 clinical trial pipeline products
Urticaria preclinical research pipeline products
Urticaria discovery stage pipeline products
Urticaria pipeline products short-term launch highlights
For more information about this report visit https://www.researchandmarkets.com/r/ha4qs5
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005657/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900